Themis Medicare Ltd., a pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, has announced the launch of a novel transdermal Estradiol spray Lenzetto in the Indian market for treatment of menopausal symptoms.

Lenzetto has clinical experience in 40 countries and is approved by USFDA and EMA for the treatment of menopausal symptoms. Lenzetto is manufactured in Europe by Gedeon Richter, the global innovators in women’s health.

Lenzetto, a novel transdermal estradiol with Metered Dose Transdermal Spray (MDTS) Technology) delivers therapeutic doses of estradiol to the skin, using a metering pump containing 1.53 mg/spray estradiol hemihydrate. Transdermal delivery of estrogen is well established in clinical practice and ensures sufficient serum estradiol levels to alleviate menopausal symptoms like hot flashes, night sweats etc. at lower overall estradiol exposure while avoiding some of the consequences of high hepatic exposure and first-pass metabolism.

Clinical studies have shown that estradiol delivered in Lenzetto 1.53 mg/spray transdermal spray formulation is absorbed through the skin and provides steady serum concentrations throughout 24 hours for the treatment of menopausal symptoms in perimenopausal and postmenopausal women.

Various studies suggest that 1.53 mg estradiol transdermal spray is a valuable HRT option, demonstrating high acceptability and satisfaction amongst menopausal women, which enhances adherence to treatment. Guidelines from various Menopause Societies around the world like British Menopause Society, International Menopause Society and North American Menopause Society recommend Transdermal as a preferred route for Estradiol for treatment of Menopausal Symptoms.

Based on the product’s benefit, Lenzetto appears to offer another therapeutic option to gynecologists for treating menopausal symptoms in women with immense clinical benefit.

Speaking at the release, Dr. Sachin Patel, Managing Director & CEO, Themis Medicare Ltd. said, “Our endeavor has always been to provide world class medicines that benefit patients and make healthcare far, far more effective. Given the fact that gynecologists currently have limited treatment options for menopausal women, Lenzetto appears to offer a much needed therapeutic option to gynecologists for treating menopausal symptoms in women with immense clinical benefit and convenience. Lenzetto will provide convenience to women as it is a transdermal spray that menopausal women can just “Spray and Go” unlike currently available transdermal Gel which are inconvenient and messy to apply. Lenzetto will be promoted by a taskforce which will exclusively meet gynecologists across the country.”

According to Themis Medicare Limited, Lenzetto is manufactured in and imported from Gedeon Richter, Hungary. Lenzetto and will be available in a Transdermal Spray that facilitates “Metered Dose Application” on to Small Skin Surface Area in a unique easy to use packaging.

With a strong R&D backup, skilled domestic & export teams, and state-of-the-art manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for major unmet medical needs and Lenzetto launch is yet another step in this direction.